

**Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2017**

Rs. in Crores

	Particulars	Quarter Ended			Year Ended
		30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
<b>1</b>	<b>Revenue from Operations</b>	<b>648.19</b>	<b>741.35</b>	<b>736.80</b>	<b>3,134.61</b>
<b>2</b>	<b>Other Income</b>	<b>0.17</b>	<b>0.89</b>	<b>0.60</b>	<b>2.47</b>
<b>3</b>	<b>Total Income</b>	<b>648.36</b>	<b>742.24</b>	<b>737.40</b>	<b>3,137.08</b>
<b>4</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	125.24	139.98	162.62	703.87
	(b) Purchase of stock-in-trade	88.26	45.10	58.75	202.13
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	(31.50)	15.40	(27.70)	(47.90)
	(d) Employee benefits expense	158.54	137.87	134.10	558.83
	(e) Finance Costs	0.89	1.81	1.28	5.12
	(f) Depreciation & Amortization Expense	21.84	21.84	19.38	82.97
	(g) Other Expenses	206.21	268.41	252.07	1,102.96
	<b>Total Expenses</b>	<b>569.50</b>	<b>630.42</b>	<b>600.50</b>	<b>2,607.99</b>
<b>5</b>	<b>Profit before tax</b>	<b>78.86</b>	<b>111.82</b>	<b>136.90</b>	<b>529.09</b>
<b>6</b>	<b>Tax Expense</b>				
	(i) Current Tax	15.48	16.49	33.27	122.40
	(ii) Deferred Tax	-	-	-	(0.21)
<b>7</b>	<b>Profit after tax for the period</b>	<b>63.38</b>	<b>95.33</b>	<b>103.63</b>	<b>406.90</b>
<b>8</b>	Share of Profit / (loss) of Associates & Joint Venture	3.29	(2.38)	0.11	(3.83)
<b>9</b>	Minority Interest	0.01	0.08	-	0.09
<b>10</b>	<b>Profit after tax and share of associate's, joint venture &amp; minority Interest</b>	<b>66.67</b>	<b>93.04</b>	<b>103.74</b>	<b>403.16</b>
<b>11</b>	<b>Other Comprehensive Income</b>				
	(i) Items that will not be reclassified to profit or loss	(1.68)	1.51	(2.19)	(2.71)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.36	(0.32)	0.47	0.58
<b>12</b>	<b>Total Comprehensive Income for the period</b>	<b>65.35</b>	<b>94.22</b>	<b>102.02</b>	<b>401.03</b>
<b>13</b>	Earnings per share - Basic & Diluted (in Rs.)	3.54	4.94	5.50	21.39



**Notes :**

- 1 The above consolidated results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 As additional information to investors, the Research and Development Expenses are provided here under

Particulars	Quarter Ended			Year Ended
	30.06.2017	31.03.2017	30.06.2016	31.03.2017
Research and Development	93.98	112.40	82.33	427.17

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 20th July, 2017



For Alembic Pharmaceuticals Limited

A handwritten signature in black ink, appearing to be "Chirayu Amin", written over a horizontal line.

Chirayu Amin  
Chairman and CEO

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2017**

Rs. In Crores

	Particulars	Quarter Ended			Year Ended
		30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
<b>1</b>	<b>Revenue from Operations</b>	<b>590.11</b>	647.03	697.35	<b>2,985.90</b>
<b>2</b>	<b>Other Income</b>	<b>0.23</b>	0.89	0.60	<b>2.42</b>
<b>3</b>	<b>Total Income</b>	<b>590.34</b>	647.92	697.96	<b>2,988.32</b>
<b>4</b>	<b>Expenses</b>				
	(a) Cost of Materials consumed	<b>125.24</b>	139.98	165.60	<b>703.87</b>
	(b) Purchase of stock-in-trade	<b>56.06</b>	41.16	62.67	<b>230.31</b>
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	<b>(13.16)</b>	15.40	(27.70)	<b>(47.90)</b>
	(d) Employee benefits expense	<b>151.30</b>	130.49	125.92	<b>527.46</b>
	(e) Finance Costs	<b>0.83</b>	1.30	0.80	<b>3.09</b>
	(f) Depreciation & Amortization Expense	<b>21.82</b>	21.83	19.07	<b>82.90</b>
	(g) Other Expenses	<b>183.83</b>	221.45	198.89	<b>938.86</b>
	<b>Total Expenses</b>	<b>525.93</b>	571.60	545.25	<b>2,438.61</b>
<b>5</b>	<b>Profit before tax</b>	<b>64.42</b>	76.32	152.71	<b>549.71</b>
<b>6</b>	<b>Tax Expense</b>				
	(i) Current Tax	<b>13.75</b>	17.08	32.97	<b>119.08</b>
	(ii) Deferred Tax	-	-	-	-
<b>7</b>	<b>Profit after tax for the period</b>	<b>50.67</b>	59.24	119.74	<b>430.63</b>
<b>8</b>	<b>Other Comprehensive Income</b>				
	(i) Items that will not be reclassified to profit or loss	<b>(1.68)</b>	1.51	(2.19)	<b>(2.71)</b>
	(ii) Income tax relating to items that will not be reclassified to profit or loss	<b>0.36</b>	(0.32)	0.47	<b>0.58</b>
<b>9</b>	<b>Total Comprehensive Income for the period</b>	<b>49.34</b>	60.42	118.02	<b>428.50</b>
<b>10</b>	<b>Earnings per share - Basic &amp; Diluted (In Rs.)</b>	<b>2.69</b>	3.14	6.35	<b>22.84</b>



**Notes :**

1 The above standalone results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.

2 As additional information to investors, the Research and Development Expenses are provided here under

Particulars	Quarter Ended			Rs. in Crores
	30.06.2017	31.03.2017	30.06.2016	Year Ended 31.03.2017
Research and Development	89.13	111.10	65.97	378.44

3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.

4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 20th July, 2017



For Alembic Pharmaceuticals Limited

A handwritten signature in black ink, appearing to be 'Chirayu Amin'.

Chirayu Amin  
Chairman and CEO

Visit us at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com)



# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

To,  
The Board of Directors,  
Alembic Pharmaceuticals Limited;  
Vadodara.

**Limited Review Report on Consolidated Quarterly Financial Results of Alembic Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

## 1. INTRODUCTION

We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of **Alembic Pharmaceuticals Limited (the Company)** wherein are included unaudited financial results of its Subsidiaries, Associates and Joint Ventures for the quarter ended on **30<sup>th</sup> June, 2017**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

This Statement has been prepared by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 which has been initialed by us for the identification purpose.

Management is responsible for the preparation and fair presentation of this consolidated interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

## 2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Offices also at  
Chennai Kolkata  
Bangaluru Coimbatore Hyderabad

**3. OTHER MATTER**

We report that the unaudited consolidated financial results have been prepared by the Company's management in accordance with and on the basis of the separate unaudited financial results of its subsidiaries, associates and joint ventures. These unaudited financial results of subsidiaries, associates and joint ventures have not been reviewed by us or any other Auditors. These are as prepared by the Company's management and included in the consolidated results as submitted to us.

The unaudited consolidated financial results of Company include

- (a) Company's share (i) in the consolidated Revenue of the Subsidiaries of Rs. 210.13 Crores for the quarter (ii) in consolidated loss of the Subsidiaries of Rs.2.31 Crores for the quarter and (iii) in the consolidated net assets of Rs.106.46 Crores as at the quarter.
- (b) Company's share in the net profit (after tax) of the Associates and Joint Venture of Rs.3.29 Crores for the quarter.

**4. CONCLUSION**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Vadodara  
Date: 20th July, 2017

For K. S. AIYAR & Co.  
Chartered Accountants  
FRN:100186W

  
Rajesh S. Joshi  
Partner  
M.No. 38526

# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

To,  
The Board of Directors,  
Alembic Pharmaceuticals Limited;  
Vadodara.

**Limited Review Report on Standalone Quarterly Financial Results of Alembic Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

## 1. INTRODUCTION

We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Alembic Pharmaceuticals Limited (the Company')** for the quarter ended on **30<sup>th</sup> June, 2017**.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

This Statement has been prepared by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 which has been initialed by us for the identification purpose.

Management is responsible for the preparation and fair presentation of this standalone interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this standalone interim financial information based on our review.

## 2. SCOPE OF REVIEW


We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Vadodara  
Date: 20th July, 2017

For K. S. AIYAR & Co.  
Chartered Accountants  
FRN:100186W



Rajesh S. Joshi  
Partner  
M.No. 38526